Phocas Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-47,746
Closed -$1.25M – 16
2026
Q2
$1.25M Sell
47,746
-2,553
-5% -$59.5K 0.17% 123
2026
Q1
$1.19M Sell
50,299
-14,200
-22% -$362K 0.19% 124
2025
Q4
$1.87M Sell
64,499
-41,808
-39% -$1.07M 0.24% 115
2025
Q3
$2M Buy
106,307
+2,293
+2% +$36.2K 0.26% 112
2025
Q2
$1.46M Buy
104,014
+15
+0% +$210 0.21% 109
2025
Q1
$1.63M Buy
+103,999
New +$1.47M 0.25% 108

Other funds holding ARQT

Phocas Financial's ARQT Position: Q3 2026 in Review

Phocas Financial sold out of Arcutis Biotherapeutics (ARQT) in Q3 2026, closing a stake of 47,746 shares — an estimated $1.25M sold.

Phocas Financial first reported a position in ARQT in Q1 2025 and held it in 6 quarters. The position peaked at $2M in Q3 2025. 293 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Phocas Financial reported no remaining Arcutis Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 47,746 Arcutis Biotherapeutics shares in Q3 2026, an estimated $1.25M.
  • Phocas Financial first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 6 quarters.
  • Phocas Financial's Arcutis Biotherapeutics position peaked at $2M in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.